Ozempic sell-off: What is Goldman saying about CSL and ResMed shares?

CSL and ResMed shares were hammered yesterday. Was it an overreaction?

| More on:
Shot of a young scientist looking stressed out while working on a computer in a lab.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

CSL Limited (ASX: CSL) and ResMed Inc (ASX: RMD) shares were under the pump on Thursday.

Both healthcare giants sank deep into the red after the market panicked over the results of another trial of the weight loss drug Ozempic. This time the wonder-drug was being trialled for the treatment of chronic kidney disease.

Ozempic delivered such strong results that the Independent Data Monitoring Committee recommended that it end as it was no longer necessary or moral to continue the study with a placebo arm.

CSL and ResMed shares fall: should you be concerned?

Goldman Sachs has been looking into the implications of the trial results on both CSL and ResMed. It highlights two areas of concern. The first is:

There is a direct link to CSL through the Vifor segment (potentially a direct earnings impact for a company which sells drugs to the kidney disease/dialysis populations, but also potential consequences for the carrying value of the business itself, which is comprised almost entirely of intangible assets and goodwill).

Another concern is that as the use cases for Ozempic grow, so too does the potential for governments and insurance companies to offer reimbursements or coverage. The high cost of Ozempic was expected to hold it back from true mass adoption, but this could potentially change. It adds:

Each positive outcome trial from NOVO or LLY broadens the potential utility of the GLP-1/GIP receptor agonist class and strengthens the argument that coverage/reimbursement should be expanded.

As we wrote here, the current c.US$1k list price of these drugs is prohibitive to the majority of those unable to secure coverage, and that is unlikely to change in the near-term. As/when payor access improves, the degree of potential threat increases for those companies positively levered to weight/diabetes/cardiovascular risk etc (e.g. RMD, FPH).

Sales impact

Fortunately for CSL, it has a very large business and multiple revenue streams. As a result, the broker estimates that just 7% to 8% of its overall revenue would be subject to the impacts of Ozempic's rise.

This could arguably make yesterday's CSL share price sell down a bit of an overreaction.

As for ResMed, the broker isn't concerned about the news and continues to believe that both Ozempic and ResMed's sleep treatment devices can co-exist. As a result, it continues to forecast strong long-term growth from ResMed and sees lots of value in its shares. It adds:

In our view, these concerns have been more than adequately priced into RMD shares, and we continue to reiterate our Buy rating. We remain Neutral-rated on CSL.

Goldman has a buy rating and $33 price target on ResMed's shares (offering 49% upside), and a neutral rating and $296.00 price target on CSL's shares (offering 24% upside).

Motley Fool contributor James Mickleboro has positions in CSL and ResMed. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended CSL, Goldman Sachs Group, and ResMed. The Motley Fool Australia has positions in and has recommended ResMed. The Motley Fool Australia has recommended CSL. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

A male doctor wearing a white doctor's coat shrugs and holds his hands up to indicate the unimpressive CSL share price as a result of OOVID-19
Share Market News

Here's why you might have just bought Healius shares

Two of the most popular super funds just loaded up on this healthcare stock.

Read more »

Doctor doing a telemedicine using laptop at a medical clinic
Healthcare Shares

Here's why this ASX 200 healthcare stock is roaring 13% higher on Wednesday

This healthcare company is outperforming every other stock within the ASX 200 today.

Read more »

A young woman sits at her desk in deep contemplation with her hand to her chin while seriously considering information she is reading on her laptop

Could CSL stock be a millionaire-maker at $261

Does the exceptional biotech company still harness the power to make an investment today worth a million in the future?

Read more »

Two happy scientists analysing test results in a lab
Healthcare Shares

Why are Mesoblast shares charging 5% higher today?

This beaten down biotech is having a strong session. But why?

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

Healius share price rallies amid corporate reset

An outgoing chair and a revitalised balance sheet. Healius is undergoing a makeover.

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

Imugene share price jumps 32% on FDA news

Here's why this biotech is having a strong start to the session.

Read more »

A medical specialist holds a red heart connected via technology and artificial intelligence (AI)
Healthcare Shares

Broker tips big gains and yields from NIB shares

Goldman Sachs is saying good things about this health insurance provider.

Read more »

A man with grahpics of robot arms, indicating a share price movement in ASX robotics and tech companies
Healthcare Shares

Up 784% in 5 years, why this ASX 200 healthcare share has a 'clear pathway' for growth in 2024

The ASX 200 stock has been a standout performer within the healthcare sector.

Read more »